Table 3.
Frequency of pSS-associated clinical manifestations and comorbidities in female and male patients with pSS
| Women n = 899% (frequency) | Men n = 68% (frequency) | p value | |
|---|---|---|---|
| Classificationa | |||
| Articular | |||
| Arthritis | 20% (169/859) | 14% (9/65) | 0.25 |
| Pulmonary | |||
| Interstitial lung disease | 6% (40/619) | 17% (8/48) | 0.008 |
| Renal | |||
| Interstitial nephritis | 3% (19/607) | 2% (1/48) | 1.00 |
| Cutaneous | |||
| Dermal vasculitis | 11% (91/836) | 8% (5/62) | 0.49 |
| Lymphadenopathy and lymphoma | |||
| Enlarged lymph nodes | 8% (69/825) | 16% (10/62) | 0.04 |
| Lymphoma | 4% (32/889) | 10% (7/68) | 0.007 |
| Muscular | |||
| Myositis | 0.9% (7/772) | 3% (2/61) | 0.14 |
| Glandular | |||
| Major salivary gland swelling | 29% (225/767) | 40% (21/53) | 0.11 |
| Presence of EGM | 34% (304/899) | 41% (28/68) | 0.22 |
| Number of EGM (mean + SD) |
0.44 ± 0.69 | 0.51 ± 0.74 | 0.30 |
| Other common comorbidities and clinical manifestations | |||
| Hypothyroidism | 24% (175/739) | 8% (4/51) | 0.009 |
| Raynaud’s phenomenon | 29% (247/851) | 30% (20/66) | 0.83 |
Italicized values indicate statistically significant findings (p < 0.05)
aAvailable data on the extraglandular manifestations evaluated to estimate the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) are included
EGM extraglandular manifestations